Company intelligence / Profile preview
GlycoEra AG
Wädenswil, Zurich, Switzerlandglycoera.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
GlycoEra AG develops first-in-class therapeutics using its proprietary CustomGlycan platform to enable targeted degradation/removal of extracellular pathogenic proteins. The company’s pipeline focuses on autoimmune, inflammatory, immuno-oncology, neurology, and infectious disease indications. All programs are currently in the preclinical stage. The company has raised significant Series A funding from leading life science investors including Bristol Myers Squibb, Roche Venture Fund, Sofinnova Partners, LimmaTech Biologics AG, and others.
- Therapeutic areas
- OncologyImmunologyNeurology
- Modalities
- Protein drugs (biologics)AntibodiesExtracellular protein degraders
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Bristol Myers SquibbLimmaTech Biologics AG
Beyond the preview
Go deeper on GlycoEra AG.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GlycoEra AG.